Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 4/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 9/20 | 0.38 |
| ▸ | CNR1 | P21554 | 8/20 | 0.38 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.35 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5757762 | 0.85 | PI4KA (0.38) | PI4KAPI4KBPIK3CGPIK3CDCNR2 | |
| SCHEMBL6588782 | 0.82 | EPHX1 (0.38) | SHMT2CHRM2CHRM1CHRM3EPHX1 | |
| SCHEMBL5753008 | 0.74 | MAPK14 (0.56) | CNR2CNR1CHRM2CHRM1CHRM3 | |
| SCHEMBL6587557 | 0.73 | EPHX1 (0.38) | SHMT2CHRM2CHRM1CHRM3EPHX1 | |
| SCHEMBL5753105 | 0.73 | MAPK14 (0.56) | CHRM2CHRM1CHRM3 | |
| SCHEMBL6585322 | 0.72 | KDM4E (0.45) | CNR2CNR1EPHX1 | |
| SCHEMBL6587109 | 0.69 | MAPK14 (0.57) | — | |
| SCHEMBL28976848 | 0.67 | PI4KA (0.54) | PI4KAPI4KBPIK3CGPIK3CDCNR2 | |
| SCHEMBL6587531 | 0.66 | MAPK14 (0.40) | — | |
| SCHEMBL6583491 | 0.66 | KDR (0.39) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030100608-A1 | 1,4-disubstituted benzo-fused cycloalkyl urea compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-05-29 | — | — | US | claimed |
| EP-1414810-B1 | 1,4-DISUBSTITUTED BENZO-FUSED CYCLOALKYL UREA COMPOUNDS | BOEHRINGER INGELHEIM PHARMA (US) | 2006-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100608-A1 | 1,4-disubstituted benzo-fused cycloalkyl urea compounds | MPO, NFKBIA, YBX1 | PI4KA 3023/4885PI4KB 1943/4885PIK3CG 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.